Adhf/ biomarkers Flashcards

1
Q

How many HF admits per year

A

1,000,000

35% of patients dead or readmitted within 60 days

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Define adhf

A

A syndrome of congestion and/or low cardiac output

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Risk factors for death in adhf

A

BUN
Blood Pressure
BNP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Nt bnp cutoff for ADHF

Biosite BNP cutoff

A

340

100

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Indications for vasodilators

A

2a if volume overloaded and not hypotensive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

3 types of bnp

A

Pro Bnp
Nt bnp not biologically active. 5-10 times more than bnp. More affected by renal fxn and age. Cut points is 125 <75, 450 if above 75
Bnp level cutoff is 100
Bnp higher in woman

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Class I indications for bnp

A

Bnp or nt bnp indicated in patients with dyspnea in which contribution of HF is not known.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

False negative bnps

A

Acute rise, obesity, acute mr

False positives:pe, Pulm Htn, acs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Groups in which bnp useful

A

ADHF, acute dyspnea, chronic HF, diastolic HF.

Do not use for screening.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How do you screen for stage b in stage a patients

A

Just physical exam. If cad should get echo.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Utility of troponin t in HF

A

Prognostic value even at low levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

3 types of bnp

A

Pro Bnp
Nt bnp not biologically active. 5-10 times more than bnp. More affected by renal fxn and age. Cut points is 125 <75, 450 if above 75
Bnp level cutoff is 100
Bnp higher in woman

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Class I indications for bnp

A

Bnp or nt bnp indicated in patients with dyspnea in which contribution of HF is not known.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

False negative bnps

A

Acute rise, obesity, acute mr

False positives:pe, Pulm Htn, acs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Groups in which bnp useful

A

ADHF, acute dyspnea, chronic HF, diastolic HF.

Do not use for screening.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How do you screen for stage b in stage a patients

A

Just physical exam. If cad should get echo.

17
Q

Utility of troponin t in HF

A

Prognostic value even at low levels

18
Q

3 types of bnp

A

Pro Bnp
Nt bnp not biologically active. 5-10 times more than bnp. More affected by renal fxn and age. Cut points is 125 <75, 450 if above 75
Bnp level cutoff is 100
Bnp higher in woman

19
Q

Class I indications for bnp

A

Bnp or nt bnp indicated in patients with dyspnea in which contribution of HF is not known.

20
Q

False negative bnps

A

Acute rise, obesity, acute mr

False positives:pe, Pulm Htn, acs

21
Q

Groups in which bnp useful

A

ADHF, acute dyspnea, chronic HF, diastolic HF.

Do not use for screening.

22
Q

How do you screen for stage b in stage a patients

A

Just physical exam. If cad should get echo.

23
Q

Utility of troponin t in HF

A

Prognostic value even at low levels

24
Q

Differences between real world and ADHF trials

A

Older, female, more hfpef, more hypertensive.

25
Q

Differences in men and women in ADHF

A

Women are older, more hypertensive and more hfpef

26
Q

How much of a rise in creatinine is a bad marker

A

.3 is a poor prognostic factor in ADHF.

27
Q

What predicts outcomes in ADHF

A

BUN <115

Creat 2.75

28
Q

If you dont know what’s going on by the time you leave the neck you are f’d

A

Yes

29
Q

Dose trial affect on renal function

A

No significant difference though slightly higher

No advantage of infusion over bolts

30
Q

Effects of unload

A

Weight loss but no improvement in sx.

Class 2a for people not responding to medical therapy.

31
Q

Ascend HF

A

No improvement in mortality
No improvement in 30 d
Modest reduction in dyspnea

32
Q

Optime trial

A

Iv milrinone versus placebo

48 hours no differences

33
Q

Goals for hospitalization

A
Oral therapy for 24 hour 
No iv drugs for 24 hours
Ambulatory 
Discharge management 
Disease management